Grant List
Represents Grant table in the DB
GET /v1/grants?page%5Bnumber%5D=1385&sort=-other_investigators
{ "links": { "first": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1&sort=-other_investigators", "last": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1397&sort=-other_investigators", "next": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1386&sort=-other_investigators", "prev": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1384&sort=-other_investigators" }, "data": [ { "type": "Grant", "id": "10559", "attributes": { "award_id": "1R01DA057052-01", "title": "Scope and impact of methadone take-home and telehealth practice changes during the COVID-19 pandemic", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute on Drug Abuse (NIDA)" ], "program_reference_codes": [], "program_officials": [ { "id": 21283, "first_name": "JULIA BETH", "last_name": "Zur", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2022-09-30", "end_date": "2026-06-30", "award_amount": 537775, "principal_investigator": { "id": 26575, "first_name": "Jan", "last_name": "Gryczynski", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 1945, "ror": "", "name": "FRIENDS RESEARCH INSTITUTE, INC.", "address": "", "city": "", "state": "MD", "zip": "", "country": "United States", "approved": true }, "abstract": "Methadone is an effective treatment for opioid use disorder (OUD) that is delivered in the U.S. through specialized Opioid Treatment Programs (OTPs). Since the inception of the OTP system many decades ago, federal regulations have required frequent clinic attendance to monitor patients’ response to treatment and reduce the risks of methadone diversion. Patients can only ‘earn’ take-home methadone after significant time in treatment while demonstrating rigid standards for adherence and stability. However, these classic regulations are not grounded in strong empirical evidence. The COVID-19 pandemic transformed service delivery practices at OTPs. To reduce crowding in clinics, SAMHSA regulators swiftly issued regulatory exemptions that gave OTPs unprecedented discretion to provide take-home methadone doses and deliver counseling via telehealth. OTPs were suddenly permitted to dispense up to 14 days of take-home methadone for ‘less stable’ patients, and 28 days for ‘stable’ patients. More recently, SAMHSA reaffirmed the regulatory exemptions and announced intentions to pursue permanent regulatory reform for OTPs. However, research is needed to examine the scope and impact of these major changes to care delivery. This study will (1) characterize practice changes at OTPs following the COVID-19 pandemic and the issuance of regulatory exemptions, (2) Examine the relationship of two major practice changes (expanded take-home methadone and telehealth practices) and patient outcomes, (3) develop a prediction model to inform decision- making about when patients can safely receive take-homes without increasing risk of negative outcomes, and (4) examine the relationship between expanded take-home methadone and methadone overdose deaths at a population level. The study will use clinical and administrative data from BayMark Health Services, the largest provider of outpatient OUD treatment in the U.S., with 100 OTPs in 23 states. Advanced analytical methods will be applied to answer the research questions, including multilevel generalized linear mixed modeling, predictive modeling and simulation methods, and interrupted time series. All analyses will consider behavioral health equity and examine disparities with respect to patients’ sex, race, and ethnicity. This study will provide critical data for regulators, OTP administrators, and practitioners. It will yield highly novel data to support evidence-driven regulatory reform, and could shape methadone treatment delivery over the next decade and beyond. The COVID-19 pandemic and associated federal exemptions offer an unprecedented opportunity to evaluate long-held assumptions about how methadone treatment should be structured to maximize its benefits while safeguarding patients and the public from unintended harm.", "keywords": [ "Adherence", "Administrator", "Admission activity", "Affect", "Area", "Behavioral", "COVID-19", "COVID-19 pandemic", "Centers for Disease Control and Prevention (U.S.)", "Cessation of life", "Clinic", "Clinical", "Coronavirus", "Counseling", "Crowding", "Data", "Death Records", "Decision Making", "Dose", "Dropout", "Drug usage", "Ethnic Origin", "Frequencies", "Goals", "Health Benefit", "Health Services", "Health Services Accessibility", "Healthcare Systems", "Home", "Individual", "Interruption", "Link", "Medicine", "Methadone", "Methods", "Modeling", "Monitor", "Opioid", "Outcome", "Outpatients", "Overdose", "Pain", "Patient Care", "Patient Monitoring", "Patient-Focused Outcomes", "Patients", "Persons", "Pharmaceutical Preparations", "Policies", "Population", "Positioning Attribute", "Provider", "Public Health", "Race", "Regulation", "Relapse", "Research", "Risk", "Series", "Shapes", "Structure", "System", "Time", "Travel", "United States Substance Abuse and Mental Health Services Administration", "advanced analytics", "analytical method", "behavioral health", "care delivery", "care seeking", "combat", "coronavirus disease", "drug testing", "effective therapy", "health equity", "indexing", "methadone treatment", "models and simulation", "mortality", "novel", "opiate tolerance", "opioid mortality", "opioid overdose", "opioid treatment program", "opioid use disorder", "overdose death", "overdose risk", "post-COVID-19", "predictive modeling", "premature", "public health emergency", "response", "service delivery", "sex", "telehealth", "transmission process", "treatment response", "trend", "willingness" ], "approved": true } }, { "type": "Grant", "id": "10560", "attributes": { "award_id": "1R01MD018340-01", "title": "Investigating and identifying the heterogeneity in COVID-19 misinformation exposure on social media among Black and Rural communities to inform precision public health messaging", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute on Minority Health and Health Disparities (NIMHD)" ], "program_reference_codes": [], "program_officials": [ { "id": 24617, "first_name": "ARIELLE SAMANTHA", "last_name": "Gillman", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2022-09-20", "end_date": "2027-05-31", "award_amount": 799507, "principal_investigator": { "id": 26576, "first_name": "SHARATH CHANDRA CHANDRA", "last_name": "GUNTUKU", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 232, "ror": "https://ror.org/00b30xv10", "name": "University of Pennsylvania", "address": "", "city": "", "state": "PA", "zip": "", "country": "United States", "approved": true }, "abstract": "PROJECT SUMMARY/ ABSTRACT In the midst of the COVID-19 pandemic, a parallel `infodemic,' an abundance of reliable information and inaccurate misinformation, persists. There has also been a significant increase in misinformation exchange and consumption, largely on social media platforms, which threatens individual and public health. An important challenge remains to develop strategies to detect trusted and accurate `signals' amidst dynamic misinformation `noise.' This misinformation contributes to confusion, distrust, and distress around health behaviors such as vaccination, mask wearing, and social distancing. The racial disparities in morbidity, mortality, social, and economic consequences of COVID-19 are well documented; less studied are variations in the information- seeking and COVID-19 health decision-making specific to Black and rural communities. Public health information and campaigns have traditionally relied on theory-based surveys or interview methods to measure knowledge and attitudes to design health messaging. Rapid expansion of social media use and parallel advances in machine learning analytics provide a unique opportunity to track public views, knowledge, and attitudes simultaneously to translate novel analytic insights into precision public health communication with an intentional lens on Black and rural communities. This proposal aims to build a computational framework to uncover heterogeneity in attitudes and misinformation exposure towards COVID- 19 vaccination, model predictors of highly engaging and persuasive messages (including sources, linguistic choices, and content); and to use pragmatic qualitative methods to understand individual response to social media misinformation with a specific lens on race (Black and white individuals) and location (rural and urban). While we focus our message development process on COVID-19 vaccination as a timely and critical behavior, and compare targeting across four specific audiences (Black rural residents, white rural residents, Black urban residents, and white rural residents), our approach is highly adaptable across health topics and scalable to a number of precision-targeted audiences. We see a need for flexible and nimble methods for rapid, human-centered content generation that supports accurate, equitable, and effective precision public health messaging. Computational tools powered by machine learning, predictive analytics, and natural language processing married with patient-centered qualitative methods offer a powerful synergy to conventional approaches to public health campaigns to identify and combat misinformation. The findings from this study will directly inform broader public health action and future strategies so that they can be deployed in the current pandemic and in ongoing efforts to address racial disparities in chronic diseases, HIV, cancer, maternal mortality, and mental health.", "keywords": [ "Address", "American", "Attitude", "Behavior", "Black American", "Black Populations", "Black race", "COVID-19", "COVID-19 impact", "COVID-19 pandemic", "COVID-19 vaccination", "Characteristics", "Chronic Disease", "Communities", "Computer Analysis", "Confusion", "Consent", "Consumption", "County", "Data", "Data Set", "Decision Making", "Development", "Distress", "Economics", "Emergency Situation", "Facebook", "Future", "Generations", "Goals", "HIV", "HIV vaccine", "Habits", "Health", "Health Campaign", "Health Disparities Research", "Health behavior", "Healthcare", "Heterogeneity", "Human", "Individual", "Institution", "Interview", "Knowledge", "Language", "Linguistics", "Location", "Longitudinal cohort", "Machine Learning", "Malignant Neoplasms", "Masks", "Maternal Mortality", "Measures", "Medicine", "Mental Health", "Methods", "Minority Groups", "Misinformation", "National Institute on Minority Health and Health Disparities", "Natural Language Processing", "Noise", "Outcome", "Patients", "Perception", "Persuasive Communication", "Politics", "Predictive Analytics", "Process", "Public Health", "Published Comment", "Qualitative Methods", "Race", "Risk", "Rural", "Rural Community", "Rural Population", "Sampling", "Signal Transduction", "Social Distance", "Source", "Structural Racism", "Structure", "Surveys", "Target Populations", "Testing", "Text", "Time", "Training", "Translating", "Trust", "Twitter", "Vaccination", "Variant", "base", "caucasian American", "combat", "computer framework", "computerized tools", "design", "disparities in morbidity", "distrust", "experience", "flexibility", "health communication", "health disparity", "health equity", "individual response", "insight", "lens", "machine learning model", "mortality", "novel", "pandemic disease", "patient oriented", "population health", "predictive modeling", "preference", "prospective", "racial disparity", "rapid technique", "recruit", "response", "rural Americans", "rural area", "rural dwellers", "social", "social media", "support tools", "synergism", "theories", "urban area" ], "approved": true } }, { "type": "Grant", "id": "10561", "attributes": { "award_id": "1R01DA057705-01", "title": "Covid-19 pandemic and changes in the prevalence, patterns, and trajectories of substance use and related health risk outcomes among young adults in WA State", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute on Drug Abuse (NIDA)" ], "program_reference_codes": [], "program_officials": [ { "id": 21884, "first_name": "PETER", "last_name": "HARTSOCK", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2022-09-30", "end_date": "2025-07-31", "award_amount": 369313, "principal_investigator": { "id": 26577, "first_name": "Katarina", "last_name": "Guttmannova", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 159, "ror": "https://ror.org/00cvxb145", "name": "University of Washington", "address": "", "city": "", "state": "WA", "zip": "", "country": "United States", "approved": true }, "abstract": "The COVID-19 pandemic has disrupted lives and affected behavioral health of many. Unhealthy changes in substance use are a great concern. Early data indicate substance use has changed during the pandemic, particularly for some sub-groups of the population. This project aims to examine changes in cannabis, alcohol, and tobacco use and related health risk behaviors (i.e. driving while—or riding with a driver—under the influence of cannabis, alcohol, and simultaneous effects of cannabis and alcohol) during the course of COVID- 19 pandemic among young adults in Washington State. Specifically, we will address the following questions: What are the patterns of young adult substance use during the pandemic and how do these relate to use before the pandemic both in terms of individual trajectories and normative patterns over the course of young adulthood? What are the predictors of escalation of use vs. desistance from use during the pandemic and what is the role of pandemic stressors in these processes? How do community-level differences in access to resources and access to substances relate to patterns of substance use during the pandemic? To answer these questions, we will use data from the WA Young Adult Health Survey (YAHS) that we collected over the past 7 years with funding from the WA State’s Division of Behavioral Health and Recovery. YAHS is an accelerated longitudinal cohort sequential study of young adults ages 18-25, with cohorts added annually and followed over time (2015-2021). Two cohorts were added after the onset of the pandemic, and five cohorts have longitudinal data spanning the time from before to during the pandemic. These data will be linked with community-level variables (e.g., neighborhood disadvantage, availability of substance use-related outlets and services) before and during the COVID-19 pandemic. We will assess changes in patterns (e.g., mode of use, sources, frequency, and amount) of cannabis, alcohol, and tobacco use, simultaneous cannabis and alcohol use, and SU-related risk behaviors (e.g., driving while intoxicated) from before to during the pandemic. The role of community-level factors and differences by socio-demographic characteristics (e.g., sex, sexual and gender minoritized status, race/ethnicity, college student status) in these changes will be examined. Moreover, we will examine within-person changes in risk factors such as norms and perceived harm of cannabis, tobacco, and alcohol use and COVID-19 pandemic related stressors by socio-demographic and community-level characteristics. Finally, we will assess within-person changes in substance use and related risk behaviors (e.g., driving while intoxicated), focusing specifically on initiation, escalation, and desistance and their predictors and potential explanatory mechanisms. Findings will inform planning of prevention and intervention efforts aimed at improving health and reducing problem behaviors.", "keywords": [ "19 year old", "21 year old", "Address", "Adult", "Affect", "Age", "Age-Years", "Alcohol consumption", "Alcohols", "Automobile Driving", "Behavior", "COVID-19 pandemic", "Cannabis", "Characteristics", "Communities", "Data", "Development", "Driving While Intoxicated", "Economics", "Education", "Ethnic Origin", "Financial Hardship", "Frequencies", "Funding", "Gender", "Health", "Health Surveys", "Healthcare", "Individual", "Intervention", "Intoxication", "Legal", "Link", "Longitudinal cohort", "Occupations", "Outcome", "Pattern", "Persons", "Population", "Prevalence", "Prevention", "Problem behavior", "Process", "Public Health", "Race", "Recovery", "Resources", "Risk", "Risk Behaviors", "Risk Factors", "Role", "SARS-CoV-2 infection", "Sales", "Sampling", "Services", "Source", "Stress", "Subgroup", "Time", "Tobacco", "Tobacco use", "Washington", "Work", "authority", "behavioral health", "cohort", "community-level factor", "coronavirus disease", "data cleaning", "differences in access", "disorder risk", "experience", "high risk", "improved", "marijuana use", "neighborhood disadvantage", "pandemic disease", "response", "secondary analysis", "sex", "sociodemographics", "stressor", "substance use", "tobacco products", "tobacco user", "university student", "vaping nicotine", "young adult" ], "approved": true } }, { "type": "Grant", "id": "10564", "attributes": { "award_id": "1R03HD107047-01A1", "title": "Data Archiving and Dissemination for Comparative Population Science", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)" ], "program_reference_codes": [], "program_officials": [ { "id": 9683, "first_name": "REGINA M", "last_name": "BURES", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2022-09-16", "end_date": "2024-08-31", "award_amount": 82250, "principal_investigator": { "id": 26581, "first_name": "Sabrina", "last_name": "Hermosilla", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 781, "ror": "", "name": "COLUMBIA UNIVERSITY HEALTH SCIENCES", "address": "", "city": "", "state": "NY", "zip": "", "country": "United States", "approved": true }, "abstract": "The creation of large, scientific studies of human behavior, social experience, and health in the general population form the cornerstone of data creation investments of the past five decades. Because the data from these studies are essential for the construction and evaluation of public policies and programs to improve the health and wellbeing of the population, NICHD places a high scientific priority on dissemination activities and tools that significantly expand the scientific use of such data. A key limitation of these dissemination efforts, thus far, is a relative dearth of data from non-U.S. populations. Dissemination of rigorous non-U.S. population data resources are urgently needed to quickly and easily test the breadth of external validity of key social, behavioral, and public health findings. We leverage NICHD’s long-term investment in the Chitwan Valley Family Study (CVFS) in Nepal to achieve this high-priority objective. The CVFS is an excellent comparative data resource, featuring a 25-year panel study from Nepal with many important features. First, the CVFS was designed to replicate features from the best longitudinal studies, such as the Panel Study of Income Dynamics and the British Household Panel Survey. Second, it was designed to measure change over time in the community level, as opposed to the individual and household levels alone. Third, the CVFS measures environmental change over time. Fourth, the CVFS follows all migrants (both individuals and households), no matter where they move, and periodically refreshes the sample with in-migrants. Finally, the CVFS has newly collected saliva-based DNA samples from all family members, blood-based anemia screening for all children, and COVID-19 disruption data on all households. Though CVFS content originally focused on family and fertility, it now includes measures from domains such as child and adolescent health. The CVFS is thus an unparalleled resource for studying NICHD priorities. We will transform access to this special resource with changes focused on use of the CVFS data, measures specially designed to facilitate comparisons, construction of new data files to speed data linking and data analysis, construction of new learning tools, and new web-based analysis tools. The activities are specifically designed to improve the transparency of comparability between CVFS and data from other settings to assist scientists making these comparisons. We will also improve data quality and user experience so the complexity of these multilevel, 25-year, multi-topic data is not an obstacle to data use. Unmatched in longevity, breadth, and its multilevel (individual, household, community) structure, the CVFS is an ideal resource for international comparative research and model testing that advances the scientific understanding of many high-priority social, behavioral, and health science questions.", "keywords": [ "American", "Anemia", "Archives", "Award", "Behavior", "Behavioral Sciences", "Blood", "British", "COVID-19", "Child", "Child Health", "Communities", "Complex", "DNA", "Data", "Data Analyses", "Data Files", "Data Set", "Demography", "Evaluation", "Family", "Family Study", "Family member", "Fertility", "Funding", "General Population", "Health", "Health Sciences", "Household", "Human", "Individual", "International", "Investments", "Journals", "Learning", "Link", "Longevity", "Longitudinal Studies", "Measures", "Migrant", "Modeling", "Modernization", "National Institute of Child Health and Human Development", "Nepal", "Online Systems", "Outcome", "Paper", "Peer Review", "Personal Satisfaction", "Population", "Population Sciences", "Public Health", "Public Policy", "Publishing", "Research", "Research Personnel", "Resources", "Saliva", "Sampling", "Scientific Advances and Accomplishments", "Scientist", "Series", "Services", "Social Sciences", "Sociology", "Speed", "Structure", "Surveys", "Testing", "Time", "Western Europe", "adolescent health", "adolescent health outcomes", "archive data", "base", "behavioral health", "comparative", "data archive", "data dissemination", "data quality", "data resource", "data sharing", "data tools", "design", "environmental change", "experience", "improved", "innovation", "panel study of income dynamics", "programs", "response", "screening", "social", "study population", "support tools", "tool", "usability", "web site" ], "approved": true } }, { "type": "Grant", "id": "10569", "attributes": { "award_id": "1DP5OD033362-01", "title": "Self-Assembling Spike-EBR Nanoparticles as a Vaccine Platform Technology Against SARS-CoV-2 and Future Pandemic Coronaviruses.", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Dental and Craniofacial Research (NIDCR)", "NIH Office of the Director" ], "program_reference_codes": [], "program_officials": [ { "id": 23244, "first_name": "Becky", "last_name": "Miller", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2022-09-15", "end_date": "2027-08-31", "award_amount": 421000, "principal_investigator": { "id": 26589, "first_name": "Magnus Adrian Gero", "last_name": "Hoffmann", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 211, "ror": "https://ror.org/05dxps055", "name": "California Institute of Technology", "address": "", "city": "", "state": "CA", "zip": "", "country": "United States", "approved": true }, "abstract": "The COVID-19 pandemic represents the 3rd outbreak caused by zoonotic transmission of a beta-coronavirus (beta-CoV) in the last 20 years. Hence there is an urgent need for new vaccine strategies to control the ongoing pandemic and prevent future CoV outbreaks. mRNA vaccines have emerged as an ideal platform for the development of rapid-response vaccines, but clinical studies have shown that neutralizing antibody titers elicited by mRNA vaccines are ~10-fold lower than titers elicited by protein nanoparticle (NP) vaccines. This is a concern with regards to the emergence of SARS-CoV-2 variants of concern (VOCs) that are less sensitive to vaccine- induced antibodies. In addition, less than 25% of the world population is fully vaccinated. Thus, rapid-response vaccine technologies are needed that elicit potent antibody responses with a single injection and/or lower doses, to ensure lasting protection against VOCs, reduce costs, and accelerate global distribution. Moreover, prevention of future CoV pandemics requires the development of a universal CoV vaccine that elicits cross-reactive immune responses against a broad spectrum of CoV strains by focusing responses to conserved epitopes. The scope of the proposed research is to design and evaluate new vaccine strategies to enhance the potency of mRNA-based rapid-response vaccines and facilitate universal CoV vaccine development. The proposal is based on the EBR NP technology, which modifies membrane proteins such as CoV spike (S) proteins to self-assemble into virus- resembling NPs that bud from the cell surface. NP assembly is induced by inserting a short amino acid sequence into the cytoplasmic tail designed to recruit proteins from the endosomal sorting complex required for transport (ESCRT) pathway. Initial studies in mice showed that low-dose injections of EBR NPs presenting the SARS- CoV-2 S protein elicited 10-fold higher neutralizing antibody titers than soluble S protein and protein-based NPs that displayed the receptor-binding domain (RBD) of the S protein. The EBR NP technology will be applied to accomplish three goals: i) Design a hybrid mRNA vaccine encoding the modified SARS-CoV-2 S-EBR construct that would be expressed at the cell surface and self-assemble into virus-resembling NPs to elicit more potent antibody responses than the approved Pfizer/Moderna vaccines, while retaining the manufacturing properties and T-cell activation of mRNA vaccines. ii) Engineer S-EBR NPs to package and deliver S or S-EBR mRNA vaccines as an alternative to lipid NPs. This delivery approach would enhance mRNA vaccine potency as S proteins presented on S-EBR NPs induce potent antibody responses, facilitate efficient intracellular delivery, and target mRNA vaccines to tissues that are naturally infected by SARS-CoV-2 to induce local immune responses. iii) Design and evaluate mosaic S-EBR NP-based universal CoV vaccine candidates that present full-length membrane-associated S proteins from multiple CoV strains to elicit cross-reactive immune responses against a broad spectrum of CoVs and protect against future outbreaks. The proposed vaccine strategies could have direct impact on the COVID-19 global health crisis and advance our emergency preparedness for the next pandemic.", "keywords": [ "2019-nCoV", "Amino Acid Sequence", "Antibody Response", "Antibody titer measurement", "Applications Grants", "Award", "B-Cell Activation", "Binding Proteins", "COVID-19 pandemic", "Cell surface", "Cells", "Clinical", "Clinical Research", "Collaborations", "Combined Vaccines", "Complex", "Coronavirus spike protein", "Cytoplasmic Tail", "Development", "Disease Outbreaks", "Dose", "Educational process of instructing", "Emergency Situation", "Encapsulated", "Engineering", "Ensure", "Epitopes", "Faculty", "Financial Support", "Funding", "Future", "Goals", "HIV-1", "Health", "Human", "Hybrids", "Immune", "Immune response", "Immunity", "Individual", "Infection", "Injections", "Institutes", "Job Application", "Laboratories", "Length", "Liquid substance", "Membrane", "Membrane Proteins", "Mentors", "Messenger RNA", "Monoclonal Antibodies", "Mosaicism", "Mus", "Pathway interactions", "Persons", "Population", "Prevention", "Production", "Property", "Protein Binding Domain", "Proteins", "RNA vaccine", "RNA-Protein Interaction", "Readiness", "Research", "Research Personnel", "Robot", "SARS-CoV-2 spike protein", "SARS-CoV-2 variant", "Sorting - Cell Movement", "System", "T-Cell Activation", "Technology", "Therapeutic", "Tissues", "Translational Research", "Vaccinated", "Vaccines", "Virus", "Zoonoses", "base", "betacoronavirus", "cost", "cost effective", "cross reactivity", "design", "graduate student", "in vivo", "industry partner", "invention", "lipid nanoparticle", "low income country", "mRNA delivery", "member", "nanoparticle", "neutralizing antibody", "novel vaccines", "pandemic coronavirus", "pandemic disease", "preclinical development", "preclinical study", "prevent", "programs", "receptor binding", "recruit", "response", "student mentoring", "transmission process", "universal coronavirus vaccine", "vaccine candidate", "vaccine delivery", "vaccine development", "vaccine platform", "vaccine response", "vaccine strategy", "vaccine-induced antibodies", "variants of concern" ], "approved": true } }, { "type": "Grant", "id": "10570", "attributes": { "award_id": "1R03HD107234-01A1", "title": "Telehealth in home visiting for new mothers: Are outcomes different if the first visits are in person?", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)" ], "program_reference_codes": [], "program_officials": [ { "id": 26590, "first_name": "Monica", "last_name": "LONGO", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2022-09-22", "end_date": "2024-08-31", "award_amount": 83750, "principal_investigator": { "id": 26591, "first_name": "Margaret Langford", "last_name": "Holland", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 452, "ror": "https://ror.org/03v76x132", "name": "Yale University", "address": "", "city": "", "state": "CT", "zip": "", "country": "United States", "approved": true }, "abstract": "Home visiting programs for new mothers have a broad range of goals, including improvements in maternal and child health, reductions in child maltreatment, and improvements in child development. Over 286,000 families facing adversity are served annually by 19 evidence-based models throughout the United States, which provide support, education, and connections to other services. Before 2020, only a small portion of visits were delivered through tele home visiting (teleHV; phone or video encounters). The Coronavirus Disease-2019 (COVID-19) pandemic required rapid adoption of teleHV; by early April 2020, 99% of home visits were by teleHV. Prior to 2020, teleHV was recommended only as a partial replacement for in-person visits and only after a relationship between the home visitor and family was established, because of the importance of the therapeutic relationship. This relationship is a key element across home visiting programs because it serves as the foundation for teaching, mentoring, and collaborating with the family. There is limited evidence regarding teleHV, although we anticipate many families will use a mix of in-person visits and teleHV after COVID-19 restrictions are lifted due to greater flexibility and other advantages. We propose a secondary data analysis to make use of this natural experiment and determine if in-person visits during the establishment of the home visitor-family relationship are associated with better outcomes than teleHV during the establishment of this relationship, and if this association is mediated by retention, relationship quality, or other process factors. We will explore if the family characteristics associated with better outcomes vary between in-person home visiting and teleHV, which will contribute to our understanding of both acceptance and effectiveness of teleHV by family characteristics. We will consider both health outcomes (maternal depressive symptoms, breastfeeding, intimate partner violence [IPV]) and process outcomes (retention, visit attendance, screening completion). We will obtain data from a large, evidence-based home visiting program, Nurse-Family Partnership (NFP). NFP has 260 sites across the United States; 1000 to 1600 pregnant first-time mothers enroll monthly, before their third trimester, and receive regular visits from nurses during pregnancy through the child’s second birthday (weekly to monthly, based on developmental stage). The NFP National Service Office collects data on all enrolled families at intake and at defined time points regarding visits, screenings, and outcomes. We have previously worked with these data and are well-positioned to access and analyze them. Our estimated sample size for the primary aim is 3000 families with in-person intake and 8000 with teleHV only. This will allow sufficient power to conduct regression analyses, controlling for family, program site, and community characteristics. This project will provide critical new knowledge about the importance of starting the home visiting relationship in-person vs. through teleHV. This knowledge will help home visiting programs better utilize teleHV in the future, resulting in better outcomes for the families served in these circumstances, including reductions in health inequities.", "keywords": [ "Adoption", "Age", "Breast Feeding", "COVID-19", "COVID-19 pandemic", "Characteristics", "Child", "Child Abuse and Neglect", "Child Development", "Child Health", "Childbirth", "Communities", "Data", "Data Analyses", "Development", "Developmental Delay Disorders", "Early Intervention", "Education", "Educational process of instructing", "Effectiveness", "Elements", "Enrollment", "Family", "Family Characteristics", "Family Nursing", "Family Process", "Family Relationship", "Family health status", "Foundations", "Frequencies", "Future", "Goals", "Health", "Home", "Home visitation", "Intake", "Knowledge", "Lead", "Lifting", "Low income", "Maternal Age", "Maternal Health", "Maternal and Child Health", "Mediating", "Mediator of activation protein", "Mental Health", "Mentors", "Modeling", "Mothers", "Natural experiment", "Nurses", "Outcome", "Persons", "Positioning Attribute", "Pregnancy", "Process", "Regression Analysis", "Risk Factors", "Sample Size", "Savings", "Screening procedure", "Services", "Site", "Social Workers", "Telephone", "Therapeutic", "Third Pregnancy Trimester", "Time", "Training", "Trust", "United States", "Visit", "Visiting Nurse", "Work", "base", "depressive symptoms", "evidence base", "experience", "family support", "flexibility", "health inequalities", "improved", "interest", "intimate partner violence", "maternal outcome", "pandemic disease", "pregnant", "programs", "recruit", "remote location", "screening", "socioeconomics", "telehealth" ], "approved": true } }, { "type": "Grant", "id": "10571", "attributes": { "award_id": "1U01IP001182-01", "title": "RFA-IP-22-004, Multidisciplinary Approach to Understanding Vaccine Efficacy and Transmission of Viral Respiratory Tract Infections in the Real World", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [], "program_reference_codes": [], "program_officials": [], "start_date": "2022-09-30", "end_date": "2027-09-29", "award_amount": 2483947, "principal_investigator": { "id": 26592, "first_name": "Stacey", "last_name": "House", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 827, "ror": "", "name": "WASHINGTON UNIVERSITY", "address": "", "city": "", "state": "MO", "zip": "", "country": "United States", "approved": true }, "abstract": "– COMPONENT A Influenza and SARS-CoV-2 are major causes of morbidity and mortality and constitute the leading causes of vaccine preventable deaths in the United States. A better understanding of vaccine effectiveness for these viral pathogens is critical to drive public health decisions and interventions. We propose utilizing a multidisciplinary approach to conduct a test-negative study to determine influenza and SARS-CoV-2 vaccine effectiveness in ambulatory patients with respiratory tract infections. The team of investigators includes experts in emergency medicine, infectious disease, pediatrics, epidemiology, information technology, molecular microbiology, virology, and genetics. This team has extensive experience in automated electronic medical record alerts, high-volume subject recruitment of ambulatory patients with respiratory tract infections, rapid escalation/de-escalation of recruitment efforts to match viral circulation patterns, respiratory and blood sample processing and shipment, quality data collection and verification, and viral genomic sequencing necessary to ensure the success of this project. The proposed study will encompass the following specific aims: 1)Utilize innovative automated alerting strategies to identify and recruit a diverse population of ambulatory patients with acute respiratory illnesses; 2) Estimate influenza and SARS-CoV-2 vaccine effectiveness using a test- negative study design in the general population as well as different demographic subgroups.; 3) Explore factors that influence influenza and SARS-CoV-2 vaccine effectiveness such as co-morbidities, vaccination type and schedule, and social determinants of health; 4) Determine effect of viral vaccination status on health outcomes in ambulatory patients with influenza and SARS-CoV-2 infection; 5) Contribute biospecimens and viral genomic sequencing data to a national repository of subjects with PCR-confirmed influenza or SARS-CoV-2 infection. To accomplish these goals, we will enroll at least 1000 ambulatory patients/year with acute respiratory tract infections in the proposed study. The subject population will be identified from the emergency departments of 3 large hospitals in the St. Louis area and their associated outpatient clinics. The available patient population at these enrolling sites is diverse with respect to race, ethnicity, age, socioeconomic status, and medical care access which will enhance the generalizability of the study outcomes to the US population.", "keywords": [], "approved": true } }, { "type": "Grant", "id": "10574", "attributes": { "award_id": "1C06OD032006-01A1", "title": "Laboratory for Combinatorial Drug Regimen Design for Resistant and Emerging Pathogens", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "NIH Office of the Director" ], "program_reference_codes": [], "program_officials": [ { "id": 23882, "first_name": "CHARLES ASHLEY", "last_name": "Barnes", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2022-09-16", "end_date": "2024-08-31", "award_amount": 5147109, "principal_investigator": { "id": 26596, "first_name": "Linden T", "last_name": "Hu", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 863, "ror": "", "name": "TUFTS UNIVERSITY BOSTON", "address": "", "city": "", "state": "MA", "zip": "", "country": "United States", "approved": true }, "abstract": "(a) Overview The past two years have shown that infectious diseases are global threats, revealing an urgent need to improve preparedness to combat unknown pathogens. Furthermore, the alarming increase in infections caused by antimicrobial resistant (AMR; see glossary, below) pathogens in recent years, exacerbated by the COVID-19 pandemic, illustrates that we are also on the verge of losing our ability to treat infections caused by known pathogens. Combination drug treatment is the therapeutic mainstay in the treatment of infections caused by several microbial pathogens, including HIV and the tuberculosis bacterium. Still, systematic and efficient development of such treatments for AMR or emerging pathogens is lacking. Tufts University (TU) is proposing to construct a new biomedical research facility, the Laboratory for Combinatorial Drug Regimen Design for Resistant and Emerging Pathogens (LCDRD), to design and develop new combinatorial therapeutic approaches for bacterial, viral, fungal, and parasitic infections and to accelerate research on AMR and emerging pandemic pathogens. The LCDRD is designed to facilitate the development of novel treatments for difficult-to-treat infections due to pathogens from both animals and humans. In addition to generating new therapies for AMR or emerging pathogens, this facility will provide diverse, well-characterized human bacterial pathogens with linked clinical data from across ‘Tufts-Medicine’, a state-wide network of hospitals serving diverse populations, for study by academia and industry. The Stuart B. Levy Tufts Center for Integrative Management of Antimicrobial Resistance (CIMAR) unites faculty from TU and Tufts Medical Center (TMC), as well as affiliate members from across the region and nation, with expertise in biomedical research, engineering, human and veterinary medicine, global health, environmental surveillance, policy, and education, to catalyze the development of new combinatorial drug strategies to treat a wide range of pathogens. Working with CIMAR in LCDRD will be the nascent Center for Emerging Infectious Diseases and Response (CEIDAR), which addresses emerging and expanding infectious disease threats such as insect-borne bacterial and viral pathogens. CEIDAR includes the Tufts Lyme Initiative and utilizes the BSL-3 level Tufts New England Regional Biosafety Laboratory (NERBL) at Tufts Cummings School of Veterinary Medicine in Grafton, an important resource for expanding work. Institutions affiliated with CIMAR/CEIDAR span a spectrum of academic and pharmaceutical interests and, although located locally at TU, will enhance transdisciplinary interactions among regional and national investigators and entities. Project Goals: The LCDRD will enable specialized and collaborative work on emerging and resistant microbial pathogens that is required to generate new combinatorial treatments. The facility will: 1) enhance interaction between clinicians and biomedical researchers to generate therapeutic antimicrobial drug regimens, particularly combination therapies, against CDCs urgent and emerging threat pathogens; 2) develop genetic and systems approaches to facilitate ‘personalized medicine’ for patients with difficult-to-treat infection; 3) provide a space where visiting scientists can receive hands-on training, allowing knowledge dissemination intra-institutionally, regionally, nationally, and globally; and 4) increase the national capacity to respond to infectious disease emergencies by providing academic and industrial entities access to libraries of well-characterized isolates for emerging pandemic and AMR pathogens. Affected Space and Requested Equipment: The LCDRD will provide a modern, centralized laboratory and collaboration capacity for a multi-institutional effort to utilize state-of-the-art research technologies to generate and characterize novel drug therapies for pathogens resistant to current therapeutic regimens as well as new pandemic threats. It will provide a specialized and biosecure environment for researchers to work with multi- drug resistant (MDR) and emerging pathogens. It will be built in an existing 2,400 sq. ft. shell space in the Biomedical Research and Public Health Building on the Tufts Health Sciences campus in Boston. The new facility, directly adjacent to Tufts’ existing BSL-3 lab and the laboratories of the PI and a key CIMAR investigator, will be shared by teams of interdisciplinary researchers from four TU schools and TMC, as well as collaborators from other regional and national institutions. Impact on Research and Clinical Practice: The National Health Security Strategy, 2019-2022, states that “the growing incidence of AMR has both public health and national security consequences” and that “expanding the antimicrobial arsenal is a real and immediate requirement to avoid an era of untreatable infectious diseases.” Through centralizing and leveraging our expertise in bacterial, viral, and MDR pathogens, innovative measures of combinatorial drug efficacy, and deep clinical expertise in treatment-resistant infections, the LCDRD will support the nation’s AMR crisis response by generating novel therapies, both at Tufts and in collaboration with other academic and pharmaceutical entities across the country (Fig. 1). LCDRD will be a national center of excellence that makes broadly available well-characterized pathogens with clinical data, allowing for linkage of patient outcomes to strain-level pathogenicity and combination therapy. This will enable a true link from bedside to bench and back—a feedback loop that will maintain a tight translational focus, inform treatment regimens for current and emerging threats, and promote personalized medicine.", "keywords": [ "Academia", "Address", "Affect", "Animals", "Antimicrobial Resistance", "Back", "Bacteria", "Bacterial Infections", "Biomedical Research", "Boston", "COVID-19 pandemic", "Centers for Disease Control and Prevention (U.S.)", "Clinical", "Clinical Data", "Collaborations", "Combined Modality Therapy", "Communicable Diseases", "Country", "Development", "Drug Combinations", "Education", "Emergency Situation", "Emerging Communicable Diseases", "Engineering", "Environment", "Equipment", "Faculty", "Feedback", "Genetic", "Glossary", "Goals", "HIV/TB", "Health", "Health Sciences", "Hospitals", "Human", "Incidence", "Industrialization", "Industry", "Infection", "Insecta", "Institution", "Knowledge", "Laboratories", "Libraries", "Link", "Measures", "Medical center", "Medicine", "Modernization", "Multi-Drug Resistance", "Mycoses", "National Security", "New England", "Parasitic infection", "Pathogenicity", "Patient-Focused Outcomes", "Patients", "Pharmaceutical Preparations", "Pharmacologic Substance", "Pharmacotherapy", "Policies", "Population Heterogeneity", "Public Health", "Readiness", "Regimen", "Research", "Research Personnel", "Resistance", "Resources", "Schools", "Scientist", "Security", "System", "Technology", "Therapeutic", "Training", "Treatment Protocols", "Universities", "Veterinary Medicine", "Veterinary Schools", "Viral", "Virus Diseases", "Visit", "Work", "antimicrobial", "antimicrobial drug", "bench to bedside", "clinical practice", "combat", "combinatorial", "design", "drug efficacy", "emerging pathogen", "global health", "improved", "innovation", "interest", "member", "multi-drug resistant pathogen", "novel", "novel therapeutics", "pandemic disease", "pathogen", "pathogenic bacteria", "pathogenic microbe", "pathogenic virus", "personalized medicine", "research facility", "response", "square foot" ], "approved": true } }, { "type": "Grant", "id": "10575", "attributes": { "award_id": "1R43GH002389-01A1", "title": "Rapid COVID-19 Mutation Discrimination Test for Global SARS-CoV-2 Variant Surveillance", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [], "program_reference_codes": [], "program_officials": [], "start_date": "2022-09-30", "end_date": "2023-03-31", "award_amount": 275766, "principal_investigator": { "id": 26597, "first_name": "Janet L", "last_name": "Huie", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 1947, "ror": "", "name": "JAN BIOTECH, INC.", "address": "", "city": "", "state": "NY", "zip": "", "country": "United States", "approved": true }, "abstract": "Public Health Problem. Covid-19 variant tracking and prevalence is greatly hindered by the lack of quick, high- throughput methods for variant detection. Covid-19 genetic variants are a current and ongoing concern, due to greater transmissibility, morbidity and potential resistance to immunity provided by vaccines. Successful surveillance will likely require full coverage: 100% of people tested (not an extrapolation of sparse or region- specific data). Jan Biotech’s proposed assay quickly detects both known variants and new variants (by detecting unknown sequences through negative results and indicating the need for sequencing) and the probes are easily adapted to detect newly emerging variants of concern and interest. The assay will allow remote and low resource area hospitals and medical centers to quickly and fully assess their community’s SARS-CoV-2 variant index for real-time, evidence-based health mandates. This is both an urgent and very likely a long term need as new variants emerge. Issues with Current Solutions & How Product Meets Unmet Needs. RT-PCR Covid-19 tests provide only a positive or negative result and do not identify genetic variants. Rapid antibody tests for Covid-19 also do not reveal variants. DNA Sequencing of the Covid-19 genome is challenging. The genome is almost 30,000 nucleotides in length and combinations of mutations in different areas of the genome are functional and identifying features of Covid-19 variants. High-throughput RNAseq methods for next-generation sequencing (NGS) require RNA purification, RT-PCR RNAseq library preparation and time-consumptive sequencing and genome assembly. Covid-19 sequencing in any format for identification of variants has not yet been CLIA- or FDA-approved. RT-qPCR assays mined for variant data rely on altered Ct curves, which are nonspecific and can be caused by variations in the assay run. The proposed rapid Covid-19 variant detection and discrimination test, performed in a multiwell plate, is variant-specific and high-throughput. Summary of Approach. We will create RNAamp oligonucleotide-templated photoreduction probe sets specific to the current most prevalent and clinically-significant Covid-19 RNA variants. We will multiplex the Covid-19 variant discrimination RNAamp tests, using different profluorophores for each target and evaluate sensitivity and reliability of multiplex results using negative human saliva samples spiked with multiple Covid-19 variant RNAs. Human samples will be used to assess commercial potential of the multiplexed Covid-19 variant RNAamp test. Covid-19 negative samples will serve as negative controls and the same negative samples spiked with Covid- 19 variant control RNAs will serve as positive controls for each variant test to achieve a statistical correlation of >0.9 with comparison assays as the metric of success. Collaborators and Unique Resources. Jan Biotech, Inc., with expertise in molecular diagnostic development, will obtain human Covid-19 positive and negative test samples from the University of Rochester Medical Center, and, as needed, from Precision for Medicine and BocaBiolistics. Specific Aims Specific Aim 1: Develop multiplexed variant discrimination RNAamp test for Covid-19 strain detection Objective 1.1: Develop and test RNAamp probe sets to differentiate Covid-19 variants of concern. Objective 1.2: Multiplex and test the Covid-19 variant discrimination RNAamp tests. Specific Aim 2: Evaluate variant discrimination RNAamp test on Covid-19 human samples Objective 2.1: Test human samples to assess commercial potential of multiplexed Covid-19 variant RNAamp. Objective 2.2: Statistical determination of assay limit of detection and specificity for each Covid-19 variant will evaluate the utility of the rapid Covid-19 variant discrimination test, including its application to pooled samples. The end result of the project will be a multiplexed Covid-19 variant discrimination test and computational software providing proof-of-concept for Phase II preclinical and clinical evaluation leading towards CLIA or 510(k) approval, clinical trials and commercialization.", "keywords": [], "approved": true } }, { "type": "Grant", "id": "10577", "attributes": { "award_id": "1C06OD034103-01", "title": "Expansion and modification of animal housing and support spaces to increase production of the NIH U42 supported pigtailed macaque colony at Johns Hopkins University", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "NIH Office of the Director" ], "program_reference_codes": [], "program_officials": [ { "id": 11602, "first_name": "GUANGHU", "last_name": "Wang", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2022-09-20", "end_date": "2027-05-31", "award_amount": 5500152, "principal_investigator": { "id": 24155, "first_name": "Eric Kenneth", "last_name": "Hutchinson", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 344, "ror": "https://ror.org/00za53h95", "name": "Johns Hopkins University", "address": "", "city": "", "state": "MD", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 344, "ror": "https://ror.org/00za53h95", "name": "Johns Hopkins University", "address": "", "city": "", "state": "MD", "zip": "", "country": "United States", "approved": true }, "abstract": "In the face of well-documented ongoing shortages of nonhuman primates for biomedical research and evidence that they may be a unique model for COVID-19, it is no surprise that the demand for pigtail macaques remains strong and continues to climb. Since the onset of NIH- support in 2006, the JHU pigtail macaque colony has provided 313 animals for biomedical research, the vast majority of which was HIV/AIDS related. With 172 of those animals (55%) going to NIH funded investigators at institutions outside of JHU, we have established our colony as an important national resource of this valuable animal model. To meet the growing need for pigtail macaques in biomedical research, we have developed a plan to significantly increase the number of animals that we can house at the JHU Research Farm and further refine our behavioral management of this breeding colony to improve productivity. First, we propose to construct an addition to the existing Building 12, significantly expanding animal housing and support spaces. This new construction will include animal housing space and innovative caging for 120 additional animals across 6 harems. This addition will also house dedicated support spaces, including an operating room, radiology room, flex holding space for convalescing or pre- sale animals, and a cage washing area, along with personnel spaces such as a staff locker room with connected showers, bathroom, laundry, and PPE donning/doffing area. Second, we propose to install underground fiber optic cable and other network infrastructure to connect the JHU Research Farm facilities to high-speed internet. This project will allow us to fully leverage the soon-to-be-installed JHU-funded upgrades to 1) security and 2) electronic animal health and behavior records. If this proposal is successful, we will better serve the NIH-funded research community that relies on primate models in two key ways: 1) we will increase the number of animals available to researchers and 2) we will evaluate the novel husbandry and behavioral management features designed into the new building and share our findings with NIH-funded nonhuman primate researchers and other national breeding centers.", "keywords": [ "AIDS/HIV problem", "Animal Housing", "Animal Model", "Animals", "Area", "Behavioral", "Biomedical Research", "Breeding", "COVID-19", "Communities", "Farm", "Fiber Optics", "Funding", "Health behavior", "Human Resources", "Institution", "Internet", "Macaca nemestrina", "Modeling", "Modification", "Network Infrastructure", "Operating Rooms", "Primates", "Production", "Productivity", "Radiology Specialty", "Records", "Research", "Research Personnel", "Resources", "Sales", "Security", "Speed", "United States National Institutes of Health", "Universities", "design", "improved", "innovation", "nonhuman primate", "novel" ], "approved": true } } ], "meta": { "pagination": { "page": 1385, "pages": 1397, "count": 13961 } } }